NCT03523975 2026-04-22
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT04903197 2026-04-01
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02446236 2026-03-24
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Phase 1 Active not recruiting
NCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT07460362 2026-03-10
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Phase 2 Recruiting
NCT05861050 2026-02-19
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Recruiting